ETF Opportunities Trust has submitted its latest NPORT-P report, which provides insights into its financial performance and investment strategies. This filing is significant as it reflects the company's ongoing commitment to transparency and accountability in the investment sector.
The report, dated October 29, 2026, covers the period ending August 31, 2026. It highlights the Kingsbarn Tactical Bond ETF, which is part of ETF Opportunities Trust's offerings. This update is particularly relevant for investors and stakeholders as it outlines the fund's asset management strategies and performance metrics.
Background
ETF Opportunities Trust is an investment company based in Richmond, Virginia. The firm is registered under the SEC Act of 1940, with a focus on managing exchange-traded funds (ETFs). The company operates under the Central Index Key (CIK) number 0001771146 and has a fiscal year ending on July 31.
What the Filing Says
The NPORT-P filing reveals that the Kingsbarn Tactical Bond ETF has total assets amounting to approximately $1,154,284.05, with total liabilities of $490.28. The net assets stand at $1,153,793.77. The report also provides detailed information on the fund's performance, including monthly total returns.
"The filing indicates a commitment to transparency and detailed reporting, which is essential for investor confidence," said Karen Shupe, Treasurer of ETF Opportunities Trust.
Impact
This filing may affect various stakeholders, including investors, financial analysts, and competitors in the ETF market. The detailed reporting of the Kingsbarn Tactical Bond ETF's performance and strategies could influence investment decisions and market trends.
What's Next
The filing does not specify what happens next, leaving stakeholders to await further updates from ETF Opportunities Trust regarding future filings or strategic changes.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






